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ABSTRACT
Objective: Our aim is to radiologically evaluate 
the effects of tamoxifen on the contralateral 
breast parenchyma in patients who have 
undergone surgery for breast cancer.
Materials and Methods: We examined the 
mammograms of 121 women; 88 of them had 
breast cancer and 33 were healthy controls. The 
patients were grouped as follows; I: patients 
who received tamoxifen therapy after surgery, II: 
patients who did not take tamoxifen and III: 
healthy controls. The breast parenchyma area, 
the visualization of Cooper’s ligaments and 
lactiferous ducts were evaluated in all 3 groups 
and analyzed statistically In order to determine 
the changes in breast density.
Results: In patients who had undergone 
tamoxifen therapy, compared to non-tamoxifen 
patients, there was a prominent reduction in 
breast parenchyma (p<0.0001). This effect was 
more significant in premenopausal women 
(p<0.005). The effect of tamoxifen was most 
evident at the first 6th month follow-up.
Conclusion: Tamoxifen reduces breast
parenchyma and mammography is an objective
method for demonstrating this reduction as a 
decrease in breast density.
K ey  W o rd s : Tamoxifen, Breast carcinoma, 
Mammography, Breast parenchyma.
INTRODUCTION
Breast cancer is the most frequently diagnosed 
cancer in women, and the second leading cause 
of female mortality in North America (1,2). 
Statistics for breast cancer in the United States 
show a recent downward trend in mortality and a 
leveling off in the incidence of breast cancer (3). 
Better treatment and diagnosis at earlier, more 
curable stages due to improved screening 
modalities have been credited with the favorable 
direction of these statistical changes (3).
Tamoxifen reduces the incidence of breast 
cancer and plays an important role in controlling 
breast cancer (3,4). Tamoxifen is a nonsteroidal 
antiestrogenic compound. It was synthesized in 
1966 in Great Britain (5) and was initially 
developed as an antifertility agent (6,7). 
Tamoxifen antagonizes estrogenic effects in the 
breast, and competes with and inhibits the
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molecular-proliferative activity of endogen 
estrogen in tumor cells. It behaves as an 
estrogen agonist in relation to bone and the lipid 
profile (3,8).
The mammographie appearance of the breast 
gained interest in recent years, and is thought to 
be a marker for breast cancer risk (9,10). The 
long-term effects of tamoxifen on the breast 
parenchyma can be evaluated In mammographie 
examinations.
Women with prior history of breast cancer have 
an approximately three times greater risk of 
developing cancer of the opposite breast, 
compared to women without breast cancer (11). 
In patients treated with tamoxifen, there is 30% 
reduction in the incidence of contralateral breast 
cancer, compared with those not treated with this 
drug (3,12). Finally, tamoxifen is said to decrease 
the breast parenchyma and this reduction 
increases the efficacy of the follow-up 
mammograms (13).
The aim of this study is to radiologically evaluate 
the effects of tamoxifen on the contralateral 
breast parenchyma in patients who have 
undergone surgery for breast cancer.
METHODS AN D  MATERIAL
We retrospectively reviewed the mammograms 
of 121 women. Eighty-eight of these women had 
breast cancer and had undergone modified 
radical mastectomy, partial mastectomy or wide 
excision. Fifty-one of these 88 breast cancer 
patients received tamoxifen treatment after 
surgery. The other 33 women were healthy and 
followed as controls.
The patients were divided into 3 groups. Group I 
consisted of 51 women who had received 
postoperative tamoxifen therapy. Group II 
(control group) consisted of 37 breast cancer 
patients who had not received tamoxifen therapy. 
Group III (control group) consisted of 33 healthy 
women who had a similar age distribution and 
menstruation status with the breast cancer 
patients.
Mammograms of the contralateral breasts were 
evaluated before and after surgery in group I and
group II, and the follow-up mammograms of the 
left breast were evaluated in group III once a year 
for at least 2 years. Two radiologists reviewed 
the mammographie examinations. Mammograms 
were taken with Senographe DMR scanner 
(General Electric Medical Systems, Milwaukee, 
W l).
The changes in breast parenchyma were 
examined on the mediolateral oblique projections 
by evaluating the changes in the area of breast 
parenchyma, the degree of visualization of 
Cooper’s ligaments and lactiferous ducts.
The area of breast parenchyma was estimated 
by multiplying the length of the longest 
horizontal axis by that of the longest vertical 
axis on the mediolateral oblique view (13). The 
changes in the area of breast parenchyma were 
grouped as:
(1) Decrease of more than 20%,
(2) Decrease of less than 20% and,
(3) No change (Fig. 1).
As the amount of breast parenchyma decreases, 
Cooper’s ligaments and lactiferous ducts 
become more visible (Fig. 2). Through this data, 
the visualization of Cooper's ligaments and 
lactiferous ducts were grouped as:
(1) Remarkable visualization,
(2) Subtle visualization, and
(3) No change.
The correlation between group I, II, III and the 
classified parameters related to the changes in 
the breast parenchyma were analyzed 
statistically. The significance of the data was 
assessed by the Chi-square test (p<0.05 was 
accepted as significant). Fischer's Exact Test 
was used to determine whether tamoxifen- 
induced parenchymal reduction was more 
prominent in premenopausal or in 
postmenopausal women (p<0.05 was accepted 
as significant).
The time interval of the most distinct effect of 
tamoxifen on breast parenchyma was also 
assessed. The changes in the area of breast 
parenchyma were evaluated in the follow-up 
mammograms and evaluated with Repeated 
Analysis of Variance test.
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Fig. 1 : The area of breast parenchyma was estimated by 
multiplying the length of the longest horizontal axis by 
that of the longest vertical axis on the mediolateral 
oblique view.
RESULTS
The mean age of the patients in group I was 55.1 
years (range, 35-75); of group II, 56.3 years 
(range, 33-75) and of group III, 53.3 years 
(range, 46-65).
Eight women in group I and one woman in group 
II were excluded because they had fatty replaced 
radiolucent breast parenchyma.
Of the 43 women in group I, 11 (25.6%) showed 
no change, 11 (25.6%) showed a decrease 
between 10-20% and 21 (48.8%) showed a 
decrease greater than 20%. In group II, no 
change in parenchymal area was assessed in 32 
(88.9%) of 36 women, a decrease of 10-20% was 
found in 4 (11.1%) women. No woman had a 
decrease greater than 20%. In the healthy control 
group (group III), all of the 33 (100%) women 
showed no change (Table I).
Through this data, a remarkable statistical 
significance was observed between the changes 
in the area of the breast parenchyma and the 
groups (p<0.0001). Compared with non­
tamoxifen patients and the healthy control group, 
there was a marked decrease in the breast 
parenchyma of patients who had undergone 
tamoxifen treatment (Figs, 2, 3). There was no 
significant difference between the non-tamoxifen 
patients and healthy women (p>0.05) (Table I).
T a b le  I: Distribution of the Changes in Parenchymal Area 
According to the Groups.
No change 10-20%
reduction
>20%
reduction
TOTAL
Tamoxifen- 11 11 21 43
treated patients 
(Group I)
(25.6%) (25.6%) (48.8%)
Non-tamoxifen 32 4 0 36
patients 
(Group II)
(88.9%) (11.1%) (0%)
Healthy patients 33 0 0 33
(Group III) (100%) (0%) (0%)
(Chi-square=34.171, p<0.0001)
All of the 43 women included in our study had 
estrogen receptor (ER) positive tumors. Of the 43 
cases in group I, 27 received only tamoxifen 
treatment, 8 received tamoxifen therapy 
combined with chemotherapy and 8 received 
tamoxifen treatment combined with chemotherapy 
and radiotherapy. In group II, 15 women received 
only radiotherapy, five received only 
chemotherapy, 6 received radiotherapy combined 
with chemotherapy and 10 had no treatment.
In group I, 19 women were premenopausal and 
24 women were postmenopausal. In group II, 13 
women were premenopausal and 23 were 
postmenopausal. In group III, 18 women were 
premenopausal and 15 were postmenopausal. 
Of the 19 premenopausal patients in group I, 18 
showed a decrease in the area of breast 
parenchyma and one showed no change. Of the 
24 postmenopausal patients in group I, 13 
showed a decrease in the area of breast 
parenchyma and 11 showed no change. 
According to this data, a more prominent 
parenchymal decrease was assessed in 
premenopausal women (p<0.05).
In healthy patients, neither premenopausal nor 
postmenopausal women showed a change in
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F ig .2 a -2 b : The reduction in parenchymal area and the remarkable visualization of Cooper's ligaments and lactiferous ducts, in the 
left mammograms, before tamoxifen treatment and after 6 months.
their breast parenchyma. The changes in the 
visualization of the lactiferous ducts in the 
Cooper’s ligaments are shown in Table II and III 
respectively.
T a b le  II: The Distribution of the Changes in Cooper’s Ligaments 
According to the Groups
No change Minimal
visualization
Remarkable
visualization
TOTAL
Tamoxifen- 12 9 22 43
treated patients 
(Group I)
(27.9%) (20.9%) (51.2%)
Non-tamoxifen 31 4 1 36
patients 
(Group II)
(86.1%) (11.1%) (2.8%)
Healthy patients 33 0 0 33
(Group III) (100%) (0%) (0%)
(Chi-square=29.101 p<0.0001)
There was a remarkable statistical significance 
between the visualization of Cooper's ligaments- 
lactiferous ducts in the groups (p<0.0001). In 
comparison with the healthy patients and non-
T a b le  III: The Distribution of the Changes in Lactiferous Ducts 
According to the Groups
No change Minimal
visualization
Remarkable
visualization
TOTAL
Tamoxifen- 12 11 20 43
treated patients 
(Group I)
(27.9%) (25.6%) (46,5%)
Non-tamoxifen 33 3 0 36
patients 
(Group II)
(91.7%) (8.3%) (0%)
Healthy patients 33 0 0 33
(Group III) (100%) (0%) (0%)
Chl-square=34 018, pcO.0001 )
tamoxifen group, there was an obvious increase 
in the visualization of Cooper’s ligaments and 
lactiferous ducts in tamoxifen patients, which 
supported the decrease in breast parenchyma. 
No statistically significant difference was found 
between group II and III according to the 
visualization of the Cooper’s ligaments and 
lactiferous ducts (p>0.05).
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F ig .3 a -3 b : The reduction in parenchymal area and the remarkable visualization of Cooper's ligaments and lactiferous ducts, in the 
right mammograms, before tamoxifen treatment and after 12 months.
The mean duration of tamoxifen therapy was
18.9 months. Patients in this group had their 
follow-up mammograms on the 12th, 18th, 24th or 
42nd months beginning from the 6th month.
The numerical value of the breast parenchyma 
was calculated and the changes in the 
parenchymal area were evaluated in the follow­
up mammograms. According to the results, the 
most obvious decrease in the area of breast 
parenchyma was seen in the first 6th month 
mammogram (Fig.2).
There was no significant difference between the 
6th and 12th-18th months (p>0.005) follow-up 
results. After 18th month, the decrease in the 
area of breast parenchyma had a horizontal 
cours.
DISCUSSION
Tamoxifen is a well-known nonsteroidal 
antiestrogenic agent that plays an important role 
in controlling breast cancer. It is also effective in 
patients in reducing the incidence of contralateral
breast cancer, compared to those who have not 
received this drug (3-8,12). Tamoxifen is 
particularly used in postmenopausal patients with 
ER-positive tumors, but it is also used in 
premenopausal women. The use of adjuvant 
tamoxifen in patients with ER-negative tumors is 
not evident. It is shown that, in long-term use of 
tamoxifen, the 10-year survival rate is increased 
in patients with both ER-positive tumors and the 
tumors of unknown ER status (3,4,12,14).
Mammographie density of the breast plays an 
important role as women who have dense breast 
parenchyma are found to have a higher risk of 
cancer, up to 4-6 fold (15). Therefore, by 
reducing breast density, tamoxifen prevents the 
development of a new breast cancer (4,9,10,13- 
18). Another advantage of the reduced density is 
that mammography becomes more efficient in 
fatty replaced breasts (4,9,13-20).
This study shows that there is a significant 
difference in the reduction of breast parenchyma 
in breast cancer patients receiving tamoxifen 
treatment compared to breast cancer patients 
who did not receive tamoxifen treatment and
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healthy controls. We found the reduction in the 
amount of breast parenchyma and improvement 
in the visualization of both Cooper’s ligaments 
and lactiferous ducts is indicative of reduction of 
the parenchyma.
Recent studies show that tamoxifen is effective in 
the reduction of breast parenchym a 
(4 ,12 ,13 ,14 ,19 ,20). In these studies, the authors 
used different methods in evaluating the 
parenchymal difference. Chow et al (20) report 
that semiquantitative or quantitative methods are 
more efficient than qualitative methods in 
showing this change. We believe that visual 
inspection solely may cause  standardization 
problems. Although we found significant 
difference in the visualization of Cooper’s 
ligaments and lactiferous ducts, we consider that 
this qualitative approach could have inter and 
intra observer differences. Measurement of the 
area of the breast parenchyma is an objective 
method and it could be easily and effectively 
used in follow-up of these patients.
While examining the effects of tamoxifen on the 
breast parenchym a, we also grouped the 
patients according to their menopausal status. 
Fatty radiolucent breasts w as excluded as there 
was no breast parenchyma to evaluate. We 
found that, the reducing effect of tamoxifen is 
more obvious in prem enopausal women 
(p<0.005). Th is finding may be due to the 
increased breast density in prem enopausal 
women, while; in postmenopausal women, the 
reduction in breast parenchyma may not be 
demonstrated due to the fatty involution. Another 
point to stress is, whether there is a transition 
from premenopausal to postmenopausal status 
during the evaluation. Th is matter is also 
emphasized in the study of Ursin et al (14). The 
investigators, without sufficient data, suggested 
that the results would not be affected by this 
transition. All the groups in our study included 
both pre-and postm enopausal women. We 
believe that the changes in breast parenchyma 
due to menopausal status should be similar in 
both tamoxifen receiving and control groups and 
the transition would not affect our results.
The relation between the reducing effect of 
tamoxifen and the time period w as also 
evaluated in our study. Of the 32 women, 10 had 
no 6th month control mammograms. In 19 cases,
the most obvious change in the breast 
parenchyma was seen in the first 6th month 
control, while the reduction at the 12th month 
control was not as remarkable. After this period, 
the reduction showed a horizontal course (Fig 4). 
There is some data in the literature that reports 
the time-dependent radiologic changes due to 
tamoxifen treatment. Son and Oh reported that 
the decrease in breast parenchyma was obvious 
after 6 months (13). Atkinson et al mentioned that 
the majority of changes in mammographic 
pattern among the cases was established within
10-25 months of tamoxifen use (19). We believe 
that, by increasing the number of cases , the 
frequency and time period of the follow-up 
mammograms; the radiologic visualization of the 
tamoxifen-induced breast parenchymal decrease 
may be debated.
In conclusions, mammographic follow-up of 
patients who were operated for breast carcinoma 
and received tamoxifen, shows a significant 
reduction of breast parenchym a of the 
contralateral breast. Th»-reduction in breast 
parenchyma is evident in the first 6th month 
follow-up. This reduction plays an important role, 
as it is believed to correlate with a decrease in 
cancer risk. Mammography can be used as an 
objective method in monitoring breast 
parenchym a in patients receiving tamoxifen 
treatment.
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